Board of Directors
Valerie Daggett, PhD
CHIEF EXECUTIVE OFFICER
AltPep is a spinout from Dr. Daggett’s University of Washington Lab in the Department of Bioengineering in the School of Medicine and College of Engineering. She has 30+ years research experience focused on protein folding, misfolding and disease. Dr. Daggett’s lab developed methods for simulations of protein conformational changes, performed the first such studies in the amyloid field and in so doing discovered the novel protein structure associated with toxicity that forms the basis of AltPep’s platform. Dr. Daggett holds a BA from Reed College, PhD from the University of California, San Francisco, and was a Postdoctoral Fellow at Stanford University.
David Goel joined our Board of Directors in December 2020. David is Co-founder and sole Managing General Partner of Matrix Capital Management Company, LP, an investment fund focused on technology and life sciences. David serves as a director on several private company boards and previously served as a director of Popular, Inc., a public financial services company. He is a member of the Board of Trustees of The Winsor School and the Museum of Fine Arts in Boston, Massachusetts. David holds a BA, magna cum laude, from Harvard University.
Joel S. Marcus
Joel S. Marcus, JD, CPA, joined our Board in December 2020. He is Executive Chairman and Founder of Alexandria Real Estate Equities, Inc/Alexandria Venture Investments, which is the preeminent developer of life science campuses with a mission to advance human health. Alexandria is an S&P 500 company with a total enterprise value of $33 billion and Alexandria Venture Investments is the company’s strategic venture capital platform. Prior to co-founding Alexandria, Joel had an extensive legal career specializing in corporate finance and capital markets, venture capital, and mergers and acquisitions. Joel received his BA and JD from UCLA.
Todd Patrick is the former CEO of Armata Pharmaceuticals (NYSE American: ARMP). Todd led the May 2019 merger of Armata’s two predecessor companies – C3J Therapeutics, where he was the President and CEO since 2010, and AmpliPhi Biosciences to create Armata. Todd earlier served as President and COO of ID Biomedical Corporation (IDB). Under his leadership, IDB grew to become the second largest influenza vaccine producer in North America prior to its acquisition by GlaxoSmithKline for $1.7 billion in 2005. In addition to AltPep and Armata, Todd is on the Board of CRH Medical Corporation (NYSE: CRHM) and the non-profit Foster Foundation.
Chad Robins is the co-founder and CEO of Adaptive Biotechnologies (NASDAQ: ADPT), a commercial-stage biotech company with an innovative platform that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Prior to co-founding Adaptive, Chad held numerous executive-level positions in medical technology, investment and real estate companies. In addition to AltPep, Chad is on the boards of Headlight, Life Science Washington, and AdvaMedDx. Chad holds an MBA from The Wharton School at the University of Pennsylvania and a BS in Managerial Economics from Cornell University.